Crinetics Pharmaceuticals Inc. (CRNX) is scheduled to make a presentation related to its drug candidate Atumelnant at the Endocrine Society's annual meeting on June 3, 2024.
Atumelnant, an oral, selective ACTH antagonist, is in development for the treatment of ACTH-dependent Cushing's syndrome and congenital adrenal hyperplasia (CAH).
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.